Genentech has reported positive results from the IMpower130 study, a Phase III trial examining the efficacy and safety of Tecentriqin combination with carboplatin and nab-paclitaxel versus chemotherapy (carboplatin and nab-paclitaxel) alone for chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC).
The multicentre, open-label, randomised trial met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS).
The results have showed that the combination of Tecentriq plus helped people live significantly longer than chemotherapy alone in the initial treatment of advanced non-squamous NSCLC.
The Tecentriq combination has also found to reduce the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone.
Safety of the Tecentriq and chemotherapy combination was also found to be consistent with the known safety profile of the individual medicines used in the trial, while no new safety signals were reported with the combination.
The IMpower130 study enrolled 724 people who were randomised equally at 1:1 ratio.
Genentech Global Product Development head and chief medical officer Sandra Horning said: “The results of the IMpower130 study add to the growing evidence showing the clinical benefit of Tecentriq-based combinations in the treatment of advanced non-squamous non-small cell lung cancer.”
Genentech is currently conducting eight Phase III lung cancer studies to investigate Tecentriq alone or in combination with other medicines for the treatment of NSCLC.
According to the American Cancer Society, NSCLC is estimated to account for 85% of all lung cancers to be diagnosed throughout this year.
Tecentriq is a monoclonal antibody that can bind with a protein called PD-L1. It can bind to PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, thereby blocking its interactions with both PD-1 and B7.1 receptors.